ARKG (ARKG)

The ARK Genomic Revolution ETF (ARKG) saw significant options trading on August 17th, with 143.26K contracts traded and 253.54K in open interest. This level of activity, including 74.5K call options and 68.76K put options, indicates substantial investor interest and varied expectations for the ETF's future performance. The options trading data suggests a dynamic environment around ARKG, reflecting both bullish and bearish sentiments among traders.

The ARK Genomic Revolution ETF (ARKG) is seen as a buy after a 15% correction, with its valuation improving and strong technical support around $34–$35. The ETF focuses on small- and mid-cap biotech companies, showing a long-term EPS growth rate of 10.7%. Despite high volatility, favorable market conditions and a rising 200-day moving average make ARKG an attractive option for growth-seeking investors willing to tolerate risk in the biotech sector.

This article provides a comprehensive profile of the ARK Genomic Revolution ETF (A14Y8G), including its dividends, returns, key statistics, and holdings. The ETF, managed by ARK Invest LLC, focuses on companies benefiting from innovations in the genomics industry, primarily in US healthcare-related sectors. It details the fund's expense ratio, inception date, and asset allocation, with a significant portion in Health Technology stocks.

This article provides a comprehensive profile of the ARK Genomic Revolution ETF (0CQL), listed on the London Stock Exchange. It covers key statistics such as Assets Under Management (AUM), expense ratio, and dividend information, alongside details about its issuer, inception date, and active management style. The fund focuses on companies benefiting from genomics innovation, primarily in North American healthcare technology, and outlines its holdings, classification, and performance metrics.

This article provides a profile of the ARKG ETF, highlighting its dividend policy and performance metrics. It explicitly states that ARKG does not pay dividends to its holders. The profile also includes sections for returns, assets under management, and fund flows, though specific data points are not provided in this overview.